Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03781960 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03781960 is a Phase 2 study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 7 participants.
The verdict
NCT03781960, a Phase 2 study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effectiveness of the combination of nivolumab and abemaciclib for the treatment of hepatocellular carcinoma. Other goals of this study are to learn about the side effects that this combination of drugs may cause and to learn more about how these drugs work by studying blood and tissue.
Interventions
- DRUG Nivolumab
- DRUG Abemaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-07-31 |
| Est. Completion | 2022-04-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03781960
The ClinicalTrials.gov registry entry for NCT03781960 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03781960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03781960 about?
NCT03781960 is a clinical study titled "Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma". The main purpose of this study is to evaluate the effectiveness of the combination of nivolumab and abemaciclib for the treatment of hepatocellular carcinoma. Other goals of this study are to learn about the side effects that this combination of drugs may cause and to learn more about how these drug...
What is the current status of trial NCT03781960?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2019-07-31. Estimated completion is 2022-04-29.
What interventions are being tested in trial NCT03781960?
The interventions under investigation include: Nivolumab (DRUG), Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT03781960?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.